Literature DB >> 24207018

Early (2008-2010) hospital outbreak of Klebsiella pneumoniae producing OXA-48 carbapenemase in the UK.

Claire P Thomas1, Luke S P Moore, Nazik Elamin, Michel Doumith, Jiancheng Zhang, Sunil Maharjan, Marina Warner, Claire Perry, Jane F Turton, Clare Johnstone, Annette Jepson, Neill D C Duncan, Alison H Holmes, David M Livermore, Neil Woodford.   

Abstract

OXA-48 β-lactamase is one of the several emerging carbapenemases. Pre-2007 reports were almost exclusively from Turkey, but subsequently its distribution has expanded. We report an early and prolonged outbreak in the UK of Klebsiella pneumoniae producing OXA-48 carbapenemase affecting a predominantly renal cohort in a West London hospital. Carbapenemase production was detected by the modified Hodge test, with confirmation by PCR for bla(OXA-48). Isolates were typed by pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST). Risk factors for acquisition were determined. Between January 2008 and April 2010, 20 K. pneumoniae isolates with reduced susceptibility to carbapenems were identified from 13 patients, comprising 12 renal cases and 1 oncology patient; 8 were outpatients and 5 were inpatients; 7 were deemed to be colonised and 6 infected, including 2 with bacteraemia, 1 of whom died. Hodge tests were positive for all isolates and all had bla(OXA-48). PFGE showed strain similarity in isolates from nine patients, whereas four patients' isolates were distinct, representing three further PFGE profiles and suggesting horizontal spread of bla(OXA-48). Most patients had received antibiotics in the preceding 3 months and all had healthcare contact, but none had recent travel to areas with endemic OXA-48 Enterobacteriaceae. The renal cohort was screened and a prevalence rate of 0.17% was found. Interventions that collectively brought the outbreak under control included strict infection control precautions, screening, improved laboratory detection protocols and antibiotic stewardship rounds.
Copyright © 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Class D β-lactamase; Infection control; Renal; Sequence type

Mesh:

Substances:

Year:  2013        PMID: 24207018     DOI: 10.1016/j.ijantimicag.2013.08.020

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  16 in total

Review 1.  Intestinal Carriage of Carbapenemase-Producing Organisms: Current Status of Surveillance Methods.

Authors:  Roberto Viau; Karen M Frank; Michael R Jacobs; Brigid Wilson; Keith Kaye; Curtis J Donskey; Federico Perez; Andrea Endimiani; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

2.  Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem.

Authors:  Jesús Oteo; Adriana Ortega; Rosa Bartolomé; Germán Bou; Carmen Conejo; Marta Fernández-Martínez; Juan José González-López; Laura Martínez-García; Luis Martínez-Martínez; María Merino; Elisenda Miró; Marta Mora; Ferran Navarro; Antonio Oliver; Álvaro Pascual; Jesús Rodríguez-Baño; Guillermo Ruiz-Carrascoso; Patricia Ruiz-Garbajosa; Laura Zamorano; Verónica Bautista; María Pérez-Vázquez; José Campos
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

3.  Molecular Characterization of OXA-48-Like-Producing Enterobacteriaceae in the Czech Republic and Evidence for Horizontal Transfer of pOXA-48-Like Plasmids.

Authors:  Anna Skalova; Katerina Chudejova; Veronika Rotova; Matej Medvecky; Vendula Studentova; Eva Chudackova; Pavel Lavicka; Tamara Bergerova; Vladislav Jakubu; Helena Zemlickova; Costas C Papagiannitsis; Jaroslav Hrabak
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

4.  A Systematic Review and Meta-analyses of the Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae.

Authors:  Karlijn van Loon; Anne F Voor In 't Holt; Margreet C Vos
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 5.  The Global Ascendency of OXA-48-Type Carbapenemases.

Authors:  Johann D D Pitout; Gisele Peirano; Marleen M Kock; Kathy-Anne Strydom; Yasufumi Matsumura
Journal:  Clin Microbiol Rev       Date:  2019-11-13       Impact factor: 26.132

6.  Forecasting carbapenem resistance from antimicrobial consumption surveillance: Lessons learnt from an OXA-48-producing Klebsiella pneumoniae outbreak in a West London renal unit.

Authors:  M Gharbi; L S P Moore; M Gilchrist; C P Thomas; K Bamford; E T Brannigan; A H Holmes
Journal:  Int J Antimicrob Agents       Date:  2015-04-23       Impact factor: 5.283

7.  Homogeneity of antimicrobial policy, yet heterogeneity of antimicrobial resistance: antimicrobial non-susceptibility among 108,717 clinical isolates from primary, secondary and tertiary care patients in London.

Authors:  Luke S P Moore; Rachel Freeman; Mark J Gilchrist; Myriam Gharbi; Eimear T Brannigan; Hugo Donaldson; David M Livermore; Alison H Holmes
Journal:  J Antimicrob Chemother       Date:  2014-08-12       Impact factor: 5.790

Review 8.  Laboratory Detection and Clinical Implication of Oxacillinase-48 like Carbapenemase: The Hidden Threat.

Authors:  Yamuna Devi Bakthavatchalam; Shalini Anandan; Balaji Veeraraghavan
Journal:  J Glob Infect Dis       Date:  2016 Jan-Mar

Review 9.  Dissemination of carbapenemases producing Gram negative bacteria in the Middle East.

Authors:  Abed Zahedi Bialvaei; Hossein Samadi Kafil; Hamed Ebrahimzadeh Leylabadlo; Mohammad Asgharzadeh; Mohammad Aghazadeh
Journal:  Iran J Microbiol       Date:  2015-10

Review 10.  Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection Methods.

Authors:  Chang-Ro Lee; Jung Hun Lee; Kwang Seung Park; Young Bae Kim; Byeong Chul Jeong; Sang Hee Lee
Journal:  Front Microbiol       Date:  2016-06-13       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.